OrthoPediatrics has seen its stock price target slashed from $39 to $23 by BTIG, indicating a significant shift in market expectations for the company. This adjustment reflects concerns about the company's future performance and could impact investor confidence. Such changes in stock price targets are crucial as they can influence trading decisions and overall market sentiment.

Truist Securities has lowered its stock price target for OrthoPediatrics to $18, indicating a more cautious outlook for the company. This adjustment reflects concerns about the company's performance and market conditions, which could impact investor confidence and future growth prospects. It's important for stakeholders to stay informed as these changes can influence investment decisions and the overall market sentiment.